Form 4: Travere Therapeutics Legal Chief Sells Shares

Elizabeth E. Reed, Travere Therapeutics' Chief Legal Officer, exercised stock options and sold 10,000 shares under a pre-arranged plan.

Summary

• Elizabeth E. Reed, Chief Legal Officer and General Counsel of Travere Therapeutics, Inc. (TVTX), reported a change in beneficial ownership.
• On January 20, 2026, Ms. Reed exercised employee stock options to acquire 10,000 shares of common stock at an exercise price of $19.08 per share.
• Concurrently, on January 20, 2026, Ms. Reed sold 10,000 shares of common stock at a weighted average sale price of $27.342 per share, with prices ranging from $26.910 to $27.590.
• The sale was executed pursuant to a Rule 10b5-1(c) written plan adopted on June 16, 2025.
• Following these transactions, Ms. Reed beneficially owns 90,270 shares of Travere Therapeutics common stock.
• The reported beneficial ownership includes 392 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 28, 2025.
• The exercised stock option was fully vested and exercisable, granted on January 4, 2017, with an expiration date of January 4, 2027.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine insider transaction involving the exercise of vested stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. Such transactions are common for executive compensation and personal financial planning and do not inherently indicate positive or negative company performance or outlook.

Positives

• The reporting person realized a profit of $8.262 per share from the exercise and sale of stock options ($27.342 sale price $19.08 exercise price).
• The sale was conducted under a pre-arranged Rule 10b5-1(c) plan, indicating a planned transaction rather than a reaction to new, non-public information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, though the impact is often mitigated by a 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction for an executive in the biotechnology industry, common for compensation and personal financial management. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minor impact, as this is a routine insider transaction under a 10b5-1 plan, which typically does not signal a change in company fundamentals. The volume of shares sold is relatively small in the context of a publicly traded company.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction where an executive exercised vested stock options and sold shares under a pre-arranged 10b5-1 plan. Such transactions are common for compensation and personal financial planning and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to alter an existing investment thesis.

Keywords

Travere Therapeutics, TVTX, Insider Transaction, Form 4, Stock Option Exercise, 10b5-1 Plan, Elizabeth E. Reed, Biotechnology